Cantargia's IL1RAP ADCs exploit IL1RAP expression by tumor cells and other cells in the tumor microenvironment (TME) to deliver toxic drugs into the tumor. The findings demonstrated safety ...

Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced that the annual report for 2024 has been published.

no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number ...